PTO/SB/08a (05-03) Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO Application Number 10/821,745 Filing Date P E INFORMATION DISCLOSURE 04/09/2004 First Named Inventor ŠŤATEMENT BY APPLICANT Snyder Art Unit 1615 Examiner Name To be assigned (Use as many sheets as necessary Attorney Docket Number 1030.004 of

The state of			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		us- 4,853,224	08/01/1989	Wong	
		us- 5,273,751	12/28/1993	Dubroff	
		US- 5,375,611	12/27/1994	Lindqvist et al.	
		us- 5,401,880	03/28/1995	Clark et al.	
		US- 5,554,187	09/10/1996	Rizzo III	
		us- 5,569,463	10/29/1996	Helmus et al.	
		US- 5,616,122	04/01/1997	Lam et al.	
		US- 5,624,704	04/29/1997	Darouiche et al.	
		^{US-} 5,743,274	04/28/1998	Peyman	
		US- 5,843,184	12/01/1998	Cionni	
		US- 5,843,186	12/1/1998	Christ	
		^{US-} 5,876,438	03/02/1999	Kelleher et al.	
		US- 5,902,283	05/11/1999	Darouiche et al.	
	Ι	us- 5,980,928	11/9/1999	Terry	
		us- 6,162,487	12/19/2000	Darouiche	
		US- 6,322,592	11/27/2001	Lucas et al.	
		US- 6,352,542	03/05/2002	Snyder	
		US-			

	FOREIGN PATENT DOCUMENTS										
Examiner Initials*	Cite No.1		atent Document e ³⁻ Number ⁴⁻ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶				
		wo	00/62760	10/26/2000	Cohan et al.						
		wo	01/32140	05/10/2001	Darougar et al.						
		wo	02/100318	12/19/2002	Varner et al.						
		EP	0544948 A1	06/09/1993	University of Miami						
		wo	03/061625	07/31/2003	Snyder et al.						

Examine Date Considered Signature *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no

considered, include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional)* See Kinds Codes of USPTO Patent Documents at <u>www.uspto.gov</u> or MPEP 901.04. *§ Exer Office that issued the document, by the two-letter code (WIPO Standard ST3). * For Japanese patent focuments, the indication of the year of the regin of the Employer must procedule the sental number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible, ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¥.	ACD LICC	eipi date. 00/1	1/200	,,		10021743 - UNU
	Under the	Paperwork Reduction Act of 198	01 A	rsone are required to re	U.S. Patent and Trader	PTO/SB/08a (05-03 oved for use through 04/30/2003. OMB 0651-003 nark Office; U.S. DEPARTMENT OF COMMERCI ion unless it contains a valid OMB control number
	Substitute	for form 1449A/PTO		5/	Con	nplete if Known
				2005 6	Application Number	10/821,745
	INFO	DRMATION BES	CLO	SUNE	Filing Date	04/09/2004
	STA	TEMENT BY	P Pdel	MEANT	First Named Inventor	Snyder
	• • • • • • • • • • • • • • • • • • • •				Art Unit	1615
		(Use as many sheets as no	cessary)	Examiner Name	To be assigned
Ū	Sheet	1	of	1	Attorney Docket Number	1030.004

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (If known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2001/0004708	06/2001	NAGAI	
		us- 5,853,760	12/1998	Cremer	
		^{US-} 6,206,916	03/2001	Furst	
		US- 2002/0099438	07/2002	Furst	
		US- 5,820,917	10/1998	Tuch	
		US-			
	1	US-			

FOREIGN PATENT DOCUMENTS								
Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶			
	KR 2001-018344A	03/2001	Choi et al. (abst. only)					
					H			
		Cite No. Foreign Patent Document Country Code 3-Number 4-Kind Code5 (if known)	Cite Foreign Patent Document Publication Date MM-DD-YYYY	Cite Foreign Patent Document Publication Date Name of Patentee or Applicant of Cited Document Country Code **Number 4*-Kind Code**(if Islamm) MM-DD-YYYY Applicant of Cited Document	Citle Foreign Patent Document Publication Date Name of Patentee or Applicant of Cited Document Revent Respect VM-Per Relevant Figures Appear			

Examiner Date Considered

"EXAMINER, Initial if reference considered, whether or not obtains is nonformance with IMPEP 809. Drew line through classics of in oil in conformance and not considered include copy of his form with next communication to applicant." Applicant's unique clastion designation number (opinion) see kinds Codes of USPTO Patent Documents at <u>www.usplo.go.</u> or MPEP 901.04. ¹² Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Lagenese patent documents, the indication of the year of the region of the Emperor wast procedule see ariel number of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. ⁶ Applicant is to place a check mark here if English language Transistion is attack.

This callection of information is required by 3T CFR 197 and 198. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confiderfallity is opened by 35 U.S. C. 122 and 3T CFR 114. This callection is estimated to late 2 brust is complete, including apthering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Originar, U.S. Patient and Trademark Office, U.S. Patient or Complete this Complete is form and/or suggestions for reducing this burden, should be sent to the Chief Information Originar, U.S. Patient and Trademark Office, U.S. Potential or the U.S. Complete is the Complete is t

EFS-Web Receipt date: 03/11/ ent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ction of information unless it contains a valid OMB control number. Under the Paperwork Reduction Act of 1995 Complete if Known Substitute for form 1449B/PTO Application Number 10/821.745 INFORMATION DUST 4/9/2004 Filing Date STATEMENT BY First Named Inventor Snyder Group Art Unit (use as many sheets as necessary) Examiner Name Attorney Docket Number Sheet of 0 1030-004

OTHER REIOR ART. MON RATENT LITERATURE DOCUMENTS								
	_	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	_					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), tills of the article (when appropriate), tille of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
		Pandey et al., Intracapsular ring sustained 5-fluorouracil delivery system for the prevention of posterior capsule opacification in rabbits: a histological study, J CATARACT REFRACT SURG 2002 Jan. 28 (1): 139-48.						
Shi W et al., Prolongation of comeal allograft survival in mice with a cyclosporine delivery system implant, CHUNG HUA YEN KO TSA CHIH 2002 Aug. 38 (8): 50								
Mantripragada, S., A lipid based depot (DepoFoam technology) for sustained release delivery, PROG LIPID RES 2002 Sep. 41 (5) 392-406.								
		Das et al., Effect of vancomycin on Staphylococcus epidermidis adherence to poly(methyl methacrylate) intraocular lenses, J CATARACT REFRACT SURG 2002 Apr. 28 (4): 703-8.						
		Cheng et al., Treatment or prevention of herpes simplex virus retinitis withintravitreally injectable crystalline 1-0-hexadecylpropanediol-3-phospho-ganciclovir, INVEST OPHTHALMOL VIC SCI 2002 Feb; 43 (2): 515-21.						
		Herrero-Vanrell et al., Biodegradable microspheres for vitreoretinal drug delivery, ADV DRUG DELIV REV 2001 Oct 31; 52 (1): 5-16						
		Herrero-Vanrell et al., Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process, PHARM RES 2000 Oct; 17 (10): 1323-8						
		Jaffe et al., Fluocinolone acetonide sustained drug delivery device to treat severe uveitis, OPHTHALMOLOGY 2000 Nov; 107 (11); 2024-33						
		Jaffe et al., Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device, INVEST OPHTHALMOL VIS SCI 2000 Oct; 41 (11); 3569-75						
		Kunou et al., Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis, J CONTROL RELEASE 2000 Aug 10; 68(2): 263-71						
		Einmahl et al., Concomitant and controlled release of dexamethasone and 5-fluorouracil from poly(ortho ester), INT J PHARM 1999 Aug 20; 185(2): 189-98						

Examiner Signature		Date Considered	
	itial if reference considered, whether or not citation is in conformance with MPEP 60 ude copy of this form with next communication to applicant.	9. Draw line throu	gh citation if not in conformance and no

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

10821745 GAU: 1611 Approved for use through 10/31/99, OMB 0651-0031

Jnde	the Paperwork Reduction Act of 1995, no persons are required to res	Palent and Tradema pond to a collection of information	ark Office; U.S. DEPARTMENT OF COMMERCE in unless it contains a valid OMB control number.	
1	Substitute for form 1449B/PTO	Complete if Known		
1		Application Number	10/821,745	
П	INFORMATION DISCLOSURE	Filing Date	4/9/2004	
П	STATEMENT BY APPLICANT	First Named Inventor	Snyder	
П	0.7.1.22.1.	Group Art Unit		
T	(use as many sheets as necessary)	Examiner Name		
ЛΤ	101	Attender Dealest Number		

Sheet	1		of	0	Attorney Docket Number	1030-004		
9								
8			C	THER PRIOR ART N	ON PATENT LITERATUR	E DOCUMENTS		
xaminer Initials	Cite No.1			k, magazine, journal, serial, sym	L LETTERS), title of the article (wi sposium, catalog, etc.), date, page y and/or country where published.	(s), volume-issue number(s),	T ²	
					fication by an intraocular-lens-t	oound sustained drug delivery system: an JRG 1996 Oct; 22 (8): 1070-9		
					lible polymers and daun 6 May; 103 (5): 800-7	orubicin in glaucoma filtration		
	Nishi et al., Effect of intraocular sustained release of indomethacin on postoperative inflammation and posterior capsule opacification, J CATARACT REFRACT SURG 1996; 22 Supp. 1: 806-10							
	Chetoni et al., Ocular mini-tablets for controlled release of timolol: evaluation in rabbits, J OCUL PHARMACOL THER 1996 Fall; 12 (3): 245-52							
	Kiremitei-Gumusderelioglu et al., A novel MMC-loaded pHEMA drainage device for the treatmen of glaucoma: in vitro and in vivo studies, J BIOMATER SCI POLYM ED 1996; 7 (1): 857-69							
	Borhani et al., Suppression of experiemental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU, INT OPHTHALMOL 1995; 19 (1): 43-9							
		Joshi A., N Spring; 10			halmic drug delivery, J	OCUL PHARMACOL 1994		
				Polysulfone capillary		ug delivery: in vitro and in		
					of an intraocular sterio OL SOC. 1999; 97: 261	d delivery system for cataract -74; discussion 274-9.		
	DuBosar, Ryan, Intraocular steriod delivery system completes FDA phase 2 trial; New drug delivery system could make postop cataract managment easier and more efficient, OCULAR SURGERY NEWS, a SLACK Incorporated newspaper, November 1, 1997.							
				F., An Intraocular Ste F OPHTHALMOLOG		or Cataract Surgery, BRITISH		

Examiner	i –	Date	
Signature		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT ACKINETES OF COMMENTATION OF THE PROPERTY OF THE PROPERT

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.